A randomized controlled clinical trial for assessing the effectiveness of pharmacogenetic information obtained with NEUROFARMAGEN in the treatment of patients with mental disorders

AB-BIOTICS S.A.0 个研究点开始时间: 2013年9月16日最近更新: 2016年1月18日

研究概览

暂无简介。

•-Patients of either sex over 18 years.
•-Patients with any of the following psychiatric diagnoses according to DSM-IV-TR: bipolar disorder, schizophrenia, major depressive disorder or obsessive-compulsive disorder
•-Patients who have given their written informed consent to participate in the study. In the case of disabled patients, informed consent of the legal representative or family member.
•-Patients with a value on the clinical global impression scale of severity (CGI-S) according to the doctor less than 4.
•-Patients who are newly diagnosed and that require medication or that are undergoing treatment and require a substitution or addition of medication with an antidepressant, antipsychotic or mood stabilizer.
•antidepresivo, antipsicótico o estabilizador del ánimo.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1800
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-Patients who are expected no to be able to complete the study.
•-Patients who are actively participating or have participated in the last three months in another clinical trial
•-Patients who are pregnant or breastfeeding, or patients who intend to become pregnant in the next 12 months.
•-Patients who are or require treatment with quinidine, cinacalcet and / or terbinafine (potent CYP2D6 inhibitors).

发起方

AB-BIOTICS S.A.